Eurofins outlines highlights from H2 2023, including organic core business growth, opening of new facilities

March 27, 2024 (Industry Intelligence Inc.) –

Eurofins released a press release on February 27, 2024 that contained highlights from H2 2023. Below are some key points from the release:

•    Eurofins recorded 8.7% organic core business growth in North America supported by the development of Environment Testing, Food Testing and BioPharma Services.

•    The company recorded +6.0% organic core business growth driven by strong performance in China, the steady expansion of BioPharma Services in India and new start-up laboratories in Australia and New Zealand.

•    Development of future biologics products and cell and gene therapies remains at a high level.

•    Eurofins increased European capacity with a new site in Lyon, France.

•    The clinical diagnostics segment experienced a strong recovery in volume in 2023 as COVID-19 related impacts have subsided.

•    During the period, Eurofins accelerated the opening of new blood collection points, with 49 collection points opening in 2023 vs 18 in 2022.

•    In North America, the BioPharma Services segment recorded strong development due to robust demand for mid-to-late phase biologics development by large- and medium-sized companies.

•    A high percentage of customers now use Eurofins’ proprietary eLIMS-BPT and LabAccess IT to manage the full life cycle of their testing needs. 

•    Eurofins Discovery has experienced market demand stabilization while demand for Discovery’s expanded biologics has increased. The company reports strong interest for the DiscoveryOne integrated discovery solutions.

•    In Clinical Diagnostics, Eurofins CellTx, a startup laboratory in Arizona, began operations supporting critical testing for living donor derived human tissue, including stem cells, bone marrow, cord blood, birth tissues, oocytes, and sperm donations. 

•    Eurofins Viracor launched two new notable tests. These include the ExPeCT™ CAR-T multiplexed, real-time qPCR assay that provides a powerful diagnostic tool to monitor and optimize CAR-T therapy for patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas. 

•    Eurofins expanded its Biopharma Services presence in India through scale-up of a recently acquired fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. 

•    In the Middle East, Eurofins acquired its first Clinical Diagnostics business in Saudi Arabia to serve the growing local market.

•    Eurofins completed the construction of its third differentiated biopharma product testing campus in France, a new 2,000 m² facility in Lentilly. The facility specializes in biopharmaceutical large molecule testing such as biochemistry, biology, microbiology, and virology.